MapLight (MPLT) files for proposed Nasdaq IPO

MapLight (MPLT) has filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. We believe our deep understanding of these causal links between the modulation of defined neural circuits and the resulting changes in disease-specific behaviors will enable us to develop therapeutics that can deliver efficacy, safety, tolerability and ease-of-use advantages to patients and prescribers."

Morgan Stanley, Jefferies, Leerink Partners, and Stifel will serve as underwriters.

You May Also Be Interested In